Metaclipse Biopharma

Metaclipse Biopharma is a clinical-stage biotechnology company focused on developing personalized cancer immunotherapies. The company utilizes its proprietary Membrane-anchored Immunostimulatory Factor (ISF) platform to create patient-specific vaccines by incorporating immunostimulatory molecules into tumor cell membranes. This approach is designed to trigger a potent and durable immune response against the patient's unique tumor antigens. Their lead program, MCB-101, is currently in clinical development for triple-negative breast cancer. Metaclipse aims to address the limitations of current immunotherapies in treating aggressive solid tumors.